Imfinzi may offer patients benefits in earlier stages of lung cancer
Last updated: 01 November 2019
You can legally access new medicines, even if they are not approved in your country.
Learn more »New clinical results show that Durvalumab improved survival (versus a placebo) in patients with non–small cell lung cancer.
Data from the trial may be added to the Imfinzi label, and suggests an important role for Imfinzi in this setting.
Read the results from the trial and more information in this Onclive article.
